PeptideX Biotech Completes Tens of Millions RMB Pre-A Financing with Riemann Hypothesis as Exclusive Financial Advisor

Shenzhen Pepsheng Biotechnology Co., Ltd. (“Pepsheng Bio” or the “Company”), creator of the world’s first trillion-scale multi-structural innovative solid-phase peptide compound library, has announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was invested by Shenzhen Fuzeng Fund Management Co., Ltd. (“Fuzeng Fund”), with Riemann-Hypothesis serving as the exclusive financial advisor. The proceeds will be primarily used for the development of the peptide compound library and team building.

Shenzhen Pepsheng Biotechnology Co., Ltd. was established in October 2022 and is the only company worldwide possessing a “comprehensive” peptide library (characterized by sequence and structural diversity, and not being a super-mixture).The company, leveraging its globally pioneering “Complex Structure Polypeptide Construction Technology,” has built the world’s firstCollectionAn entity-based peptide library featuring structural and sequence diversity, coupled with a comprehensive technology platform for peptide drug discovery, screening, and optimization, will significantly overcome the bottlenecks of difficult discovery and optimization in peptide therapeutics. This platform provides CRO services for the discovery, screening, and optimization of bioactive peptides—including aesthetic active peptides, targeted delivery peptides, and transdermal delivery peptides—to biopharmaceutical companies worldwide.

Founded under the leadership of Dr. Wang Zhuyin, the company’s core team members all hold overseas doctoral or postdoctoral degrees and have work experience at world-class pharmaceutical companies. The company’s R&D team comprises nearly 50 professionals. It has established core functional libraries targeting cell-penetrating peptides, antimicrobial peptides, transdermal peptides, and active peptides for medical aesthetics. To date, the company has identified multiple cell-penetrating peptides, several antimicrobial peptides, and various active peptides for medical aesthetics. Furthermore, it has advanced multiple bioactive peptides with demonstrated efficacy in combating high-altitude hypoxia, treating osteoporosis, and promoting bone injury healing into the candidate drug stage. The founder and core team members have collectively filed over 80 patents, published more than 200 academic papers, and established over 200 drug testing methods. They possess extensive experience covering the entire workflow from drug discovery to preclinical studies, including peptide library construction, high-throughput drug screening, and optimization. The team combines profound scientific research expertise with strong industrial backgrounds, achieving complementary advantages.

Leveraging its globally leading innovative peptide library—a veritable “gold mine”—the company continuously explores high-end innovative active peptide ingredients (such as complex-structured peptides like conopeptides), striving to become the world’s largest CDMO provider of active peptide ingredients with independent intellectual property rights. Conopeptides (conotoxins), derived from tropical marine mollusks, exhibit potent muscle contraction-inhibiting effects, enabling rapid wrinkle reduction, skin smoothing, and firming, and have been widely applied in high-end cosmetics. However, due to the unique four-ring three-dimensional rigid structure and multiple disulfide bonds of conopeptides, their manufacturing process is complex, resulting in low yields and high costs, which hinders widespread adoption. Shenzhen Pepsheng Biotechnology Co., Ltd. has developed various active conopeptide molecules based on its proprietary technology for constructing libraries of complex peptide structures. Furthermore, through innovative peptide production processes, the company can significantly reduce production costs. By utilizing its peptide performance evaluation platform—which assesses biological activity, membrane permeability, transdermal delivery, and safety—the company can deliver conopeptides with superior market performance, positioning itself to become a globally leading CDMO provider of active conopeptide ingredients.

Dr. Wang Zhuyin, Founder of Pepsheng Biotechnologystated: “We extend our sincere gratitude to the company’s strong and professional founding team for their continuous efforts, and to our investors for their steadfast support and trust. The successful completion of this financing round is a full recognition of Pepsheng Biotechnology’s operational capabilities and the development potential of its technology platform. Moving forward, the company will leverage its proprietary ‘comprehensive’ innovative peptide physical compound library to provide customers with end-to-end CRO services for peptide discovery, screening, and optimization, as well as CDMO services for active peptide raw materials with independent intellectual property rights. By delivering ‘high quality at competitive prices—premium yet affordable,’ we are committed to becoming the world’s largest provider of peptide CRO and active peptide raw material CDMO services with independent intellectual property rights.”

Fuzeng Fund“We are delighted to participate in Shenzhen Pepsheng Biotechnology Co., Ltd.’s Pre-A financing round. A physical library of peptide compounds constitutes core infrastructure for peptide drug discovery. Traditional peptide libraries suffer from significant limitations, including structural homogeneity, low sequence diversity, and a predominance of highly complex mixtures. However, peptide activity depends not only on sequence but also, and more critically, on structural diversity. These constraints make it difficult to discover high-quality bioactive peptides using traditional libraries. Pepsheng’s proprietary, comprehensive innovative peptide library effectively addresses these shortcomings, offering transformative industrial value. It is poised to reshape the landscape of bioactive peptide discovery and, leveraging this globally leading innovative platform, enable a continuous supply of innovative bioactive peptide materials through CDMO services. The founding team brings extensive management experience, robust industry resources, and deep technological expertise, all of which underpin our strong confidence in Pepsheng’s rapid future growth.”

As the exclusive financial advisor for this round of financing,Dr. Li Chaoxing, Chairman of Riemann-HypothesisIt stated: “The slow development of peptide drugs is fundamentally attributed to the difficulty in discovering high-quality bioactive peptides and the lengthy optimization cycles. Shenzhen Pepsheng Biotechnology Co., Ltd. possesses a full-process peptide drug discovery technology platform. Its globally unique innovative peptide library construction technology enables the creation of a ‘comprehensive’ peptide library with diverse sequences and structures, excluding super-mixtures, thereby addressing the pain point of difficult bioactive peptide discovery. Furthermore, its globally leading innovative molecular optimization technology resolves the challenge of optimizing peptide molecules. Leveraging its complete closed-loop industrial technology for peptide discovery, Shenzhen Pepsheng Biotechnology can more efficiently identify peptide molecules with superior structures and higher potency, ensuring that the difficulties in discovering and optimizing bioactive peptides no longer remain industry pain points. Meanwhile, its CDMO services, based on unique synthesis processes, will provide the market with a continuous supply of bioactive peptide raw materials at significantly reduced costs.”

Shenzhen Fuzeng Fund Management Co., Ltd. was established in April 2016. Its team members possess extensive experience in investment and capital operations, and the firm currently manages nearly RMB 500 million in fund assets. Adhering to an investment philosophy of “investment + comprehensive empowerment,” Fuzeng Fund is committed to maximizing value for investors. By analyzing and leveraging opportunities arising from industry cycles, the firm strategically positions itself in multiple high-growth niche sectors to deliver long-term, stable returns. Fuzeng Fund focuses primarily on early-stage and growth-stage projects in the healthcare and medical wellness sector.

Riemann-Hypothesis, founded by Dr. Li Chaoxing upon his return from the United States in 2018, is an integrated platform for “institutionalized” industrial innovation focused on the early stages of life sciences. Adhering to its original mission of collaborating with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations, Riemann-Hypothesis is dedicated to providing early-stage investment and “full-service” operational incubation for original and pioneering biomedical projects worldwide. It has fully established its proprietary “institutionalized” incubation system, thereby breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.